Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Recruiting 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 3Triple Negative Breast Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 1Non-Muscle Invasive Bladder Neoplasms 1Carcinoma, Adenoid Cystic 1

Interventions

Letrozole 25Fulvestrant 25Specimen Handling 19ribociclib 16Capecitabine 16pembrolizumab 14palbociclib 14Paclitaxel 14Trastuzumab 13Carboplatin 13exemestane 12abemaciclib 12Tamoxifen 12Anastrozole 12Magnetic Resonance Spectroscopy 11trastuzumab deruxtecan 8pertuzumab 8Biopsy 8Goserelin 7inavolisib 6giredestrant 6Cyclophosphamide 6130-nm albumin-bound paclitaxel 6patritumab deruxtecan 5eribulin 5elacestrant 5Taxes 5Standard of Care 5Radiotherapy 5Gonadotropin-Releasing Hormone 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Breast Neoplasms × Epirubicin × 30 days × Clear all
NCT06966700 2026-06-01

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Merck Sharp & Dohme LLC

Phase 3 Recruiting
2,400 enrolled
Breast

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05582499 2026-05-28

FASCINATE-N

Fudan University

Phase 2 Recruiting
716 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06797635 2026-05-20

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

Merck Sharp & Dohme LLC

Phase 2 Recruiting
372 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡